University of Wisconsin School of Medicine and Public Health, Department of Medicine, Madison, Wisconsin.
West J Emerg Med. 2012 Feb;13(1):63-7. doi: 10.5811/westjem.2011.3.6696.
Sulfobutylether-β-cyclodextrin (SBE-CD) is a pharmaceutical excipient known to bind verapamil. Following intravenous administration, clearance of SBE-CD approximates glomerular filtration rate. We hypothesized that infusion of SBE-CD would increase time to asystole in a rat model of verapamil toxicity in a dose-dependent manner. The objective was to demonstrate the effect of a range of SBE-CD concentrations in a rat model of verapamil toxicity.
Twenty-five Wistar rats were allocated to control or 1 of 4 intervention groups. All received ketamine and diazepam anesthesia followed by verapamil infusion 32 mg/kg/h. The verapamil infusion for the intervention groups was premixed with SBE-CD in a 1:1, 1:2, 1:4, or 1:8 molar ratio (verapamil to SBE-CD). The control group infusion did not contain SBE-CD. Additional saline or water was added to the infusion so that the total volume infused was the same across groups, and the osmolality was maintained as close to physiologic as possible. Heart rate, respiratory rate, and temperature were monitored. The primary endpoint was time to asystole.
Verapamil coinfused with SBE-CD in a molar ratio of 1:4 resulted in prolonged time to asystole compared to control (21.2 minutes vs 17.6 minutes, P < 0.05). There were no differences in time to asystole between control and any other intervention group. There was no significant difference in time to apnea between control and any intervention group. We assessed the effect of a range of SBE-CD concentrations and identified 1 concentration that prolonged time to asystole. Mechanisms that may explain this effect include optimal volume expansion with a hyperosmolar cyclodextrin containing solution, complexation of verapamil within the hydrophobic cyclodextrin pore, and/or complexation within micelle-like aggregates of cyclodextrin. However, mechanistic explanations for the observed findings are speculative at this point.
The 1:4 verapamil to SBE-CD concentration was modestly effective with SBE-CD concentrations above and below this range demonstrating nonstatistically significant improvements in time to asystole.
磺丁基醚-β-环糊精(SBE-CD)是一种已知可与维拉帕米结合的药物赋形剂。静脉给药后,SBE-CD 的清除率接近肾小球滤过率。我们假设,在维拉帕米毒性的大鼠模型中,以剂量依赖性方式输注 SBE-CD 会延长心脏停搏时间。目的是在维拉帕米毒性的大鼠模型中证明一系列 SBE-CD 浓度的影响。
将 25 只 Wistar 大鼠分配到对照组或 4 个干预组中的 1 个。所有大鼠均接受氯胺酮和地西泮麻醉,然后以 32mg/kg/h 的速度输注维拉帕米。干预组的维拉帕米输注液与 SBE-CD 以 1:1、1:2、1:4 或 1:8 的摩尔比(维拉帕米与 SBE-CD 的摩尔比)预先混合。对照组的输注液不含 SBE-CD。向输注液中添加额外的生理盐水或水,以使各组的输注总量相同,并尽可能接近生理渗透压。监测心率、呼吸频率和体温。主要终点是心脏停搏时间。
以 1:4 的摩尔比与 SBE-CD 共输注的维拉帕米导致心脏停搏时间延长,与对照组相比(21.2 分钟比 17.6 分钟,P<0.05)。与对照组相比,其他任何干预组之间的心脏停搏时间没有差异。与对照组相比,任何干预组之间的呼吸暂停时间均无显著差异。我们评估了一系列 SBE-CD 浓度的影响,并确定了一种可延长心脏停搏时间的浓度。可能解释这种效果的机制包括含有高渗环糊精的溶液的最佳容量扩张、维拉帕米在疏水性环糊精孔内的络合、以及/或环糊精胶束样聚集体内的络合。然而,目前观察到的发现的机制解释只是推测性的。
1:4 的维拉帕米与 SBE-CD 浓度对 SBE-CD 浓度具有适度的效果,高于和低于该范围的浓度显示心脏停搏时间的非统计学显著改善。